The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy

Prostate

Volumn 73, Issue 16, 2013, Pages 1796-1802

  Elshafei, Ahmed ^a   Li, Yong Hong ^a   Hatem, Asmaa ^a   Moussa, Ayman S ^a   Ethan, Vargo ^a   Krishnan, Nirmal ^a   Li, Jianbo ^a   Jones, J Stephen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

prostate biopsy; prostate specific antigen velocity; prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ATYPICAL SMALL ACINAR PROLIFERATION; CANCER DIAGNOSIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; PROSTATE VOLUME; TRANSRECTAL ULTRASONOGRAPHY;

PROSTATE BIOPSY; PROSTATE SPECIFIC ANTIGEN VELOCITY; PROSTATIC NEOPLASM;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84886948883     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22718     Document Type: Article

References (23)

1. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS,. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011; 186 (3): 850-854.
2. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M,. Prospective evaluation of prostate cancer detected on biopsies 1, 2 3, and 4: When should we stop ? J Urol 2001; 166 (5): 1679-1683.
3. Keetch DW, McMurty JM, Smith DS, Andriole GL, Catalona WJ,. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996; 156: 428-431.
4. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity & doubling time as predicators for prostate cancer. J Clin Oncol 2009; 27 (3): 398-403.
5. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM,. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99: 1510-1515.
6. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351 (2): 125-135.
7. Klotz L, Teahan S,. Current role of PSA kinetics in the management of patients with prostate cancer. Eur Urol 2006; 5 (6): 471-536.
8. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G,. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers 2002; 17 (2): 79-83.
9. Roobol MJ, Kranse R, de Koning HJ, Schröder FH,. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM). Urology 2004; 63 (2): 309-313; discussion 313-315.
10. Wolters T, Roobol MJ, Bangma CH, Schröder FH,. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009; 55 (2): 385-392. doi: 10.1016/j.eururo.2008.02.046 [Epub2008. Mar 11].
11. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM,. An empirical evaluation of guidelines on prostate specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103 (6): 462-469.
12. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M,. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160 (2): 411-418, discussion 418-419.
13. Fowler JE Jr, Bigler SA, Miles D, Yalkut DA,. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol 2000; 163 (3): 813-818.
14. Ciatto S, Rubeca T, Confortini M, Pontenani G, Lombardi C, Zendron P, Di Lollo S, Crocetti E,. Free to total PSA ratio is not a reliable predictor of prostate biopsy outcome. Tumori 2004; 90 (3): 324-327.
15. Benecchi L, Pieri AM, Destro Pastizarro C, Potenzoni M,. Optimal measure of PSA kinetics to identify prostate cancer. Urology 2008; 71 (3): 390-394.
16. Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ,. Can prostate-specific antigen velocity thresholds decrease insignificant cancer detection ? J Urol 2010; 183 (1): 112-116.
17. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK,. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007; 109 (8): 1689-1695.
18. Roobol MJ, Kranse R, De Koning HJ, Schröder FH,. Prostate-specific antigen at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam). Urology 2004; 63 (2): 309-313; discussion 313-315.
19. Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H,. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol 2010; 184 (3): 907-912.
20. Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ,. PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness. Urology 2008; 72 (5): 1116-1120, discussion 1120.
21. Punglia RS, Cullen J, Mcleod DG, Chen Y, D'Amico AV,. Prostate-specific antigen velocity and the detection of Gleason score 7 to 10 prostate cancer. Cancer 2007; 110 (9): 1973-1978.
22. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ,. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012; 109 (4): 508-513, discussion 513-514.
23. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF,. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52 (4): 1044-1050.